More articles from Current Drug Therapy
- Labetalol and other agents that block both alpha- and beta-adrenergic receptors
A review of how these agents can be used in managing difficult-to-control hypertension.
- Hepatic toxicity of antirheumatic drugs
Drug treatment of rheumatic diseases is associated with a small but well-documented risk of hepatotoxicity. Recognizing the clinical syndromes associated with liver injury by these agents facilitates the minimization of morbidity from this complication.
- The role of azithromycin and clarithromycin in clinical practice
Clinical trials show these to be excellent alternatives to conventional agents for treating infections of the respiratory tract, skin, and skin structures. Their high cost, however, may prohibit routine use.
- Pheochromocytoma: current diagnosis and management
In patients with paroxysmal or sustained hypertension, especially if symptoms are present, pheochromocytoma should be suspected.
- Primary aldosteronism: new approaches to diagnosis and management
Uncertainties persist regarding optimal screening methods, the diagnostic process, diagnostic criteria, and differentiation of the growing number of etiological subgroups.
- From bathtub ring to osteoporosis: a clinical review of the bisphosphonates
BACKGROUND Etidronate and pamidronate are bisphosphonates, a class of chemical compounds originally used to soften hard water and prevent soap scum. Etidronate was serendipitously found to abate calcification in a child with myositis ossificans progressiva.
OBJECTIVE Review the basic pharmacology of these compounds, as well as clinical uses of the approved and nonapproved forms.
DISCUSSION Etidronate is approved for the treatment of hypercalcemia, Paget’s disease of bone, and ectopic calcification, and has been used to treat hyperparathyroidism and nephrolithiasis with limited success. Recently it has been used to treat osteoporosis. Pamidronate is approved to treat hypercalcemia. These two drugs are the only bisphosphonates available in the United States.
CONCLUSIONS Clinical trials with etidronate have aroused widespread interest in the application of bisphosphonates to treat osteoporosis. Many trials are underway to evaluate these new drugs. More information will be available within the next 5 years.
- The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure: insights and highlights from the chairman
Highlights include the new classification schema and recommendations on the use of labetalol.
- Assessing hypertension management: the role of 24-hour blood pressure monitoring
BACKGROUND The first fully automatic portable invasive blood pressure recorder was developed 30 years ago. Today, portable noninvasive ambulatory blood pressure devices are capable of measuring blood pressure intermittently for periods of 24 to 48 hours.
OBJECTIVE To discuss the utility of automatic ambulatory blood pressure recording in assessing antihypertensive therapy.
SUMMARY Ambulatory blood pressure monitoring is helpful in assessing the pharmacodynamics and the clinical efficacy of an-tihypertensive drugs. It is superior to office blood pressure measurement in predicting hypertensive end-organ disease. In clinical trials, ambulatory blood pressure monitoring permits a more varied population to enter a study, the number of subjects required is often reduced, and a placebo control group may be unnecessary.
CONCLUSIONS The various methods of analyzing ambulatory blood pressure data should be used in a complementary fashion to evaluate antihypertensive drug therapy. We believe that this technique will soon become much more commonly used for hypertension management.
- The use of G-CSF and GM-CSF in bone marrow transplantation
Using hematopoietic growth factors appears to have made bone marrow transplantation safer. Treatment-related morbidity and mortality have decreased, and patients are discharged from the hospital sooner.
- Theophylline in the ambulatory treatment of chronic obstructive lung disease: resolving a controversy
BACKGROUND Recent reports of a high frequency of theophylline toxicity, which usually occurs at theophylline blood levels >20 μg/mL, coupled with the recent addition of metered-dose, inhaled anticholinergics to the beta-2 agonist inhalers already available for treatment of chronic obstructive pulmonary disease, has led some authors to suggest that theophylline should no longer be used in the ambulatory management of this disease.
OBJECTIVE The author suggests an alternate approach to theophylline dosing as a means of resolving the current controversy.
SUMMARY Because of the log-linear relationship between bronchodilation and blood level, little bronchodilator efficacy is lost by using a target therapeutic theophylline blood level of 10 ± 2 μg/mL. This target provides a greater range between therapeutic and toxic blood levels than the 17 ± 2 μg/mL therapeutic target blood level that has also been recommended.
CONCLUSIONS Because theophylline has a different mode of action than the sympathomimetic or anticholinergic drugs, it continues to have a useful place in the ambulatory management of chronic obstructive pulmonary disease.